Among these are two common alleles, the "I" (IVS2+ 1) and "A" (P426L) alleles,4 associated with infantile and later onset MLD respectively. These two alleles together account for 54% of MLD alleles. There is also a pseudodeficiency associated with arylsulphatase A in which enzyme levels are significantly reduced without any clinical or biochemical evidence of disease.5 The pseudodeficiency allele (Pd) occurs at 10-20% in the general population. This Pd allele consists of a complex of two mutations, a glycosylation site mutation (N350S) in exon 6 affecting the third glycosylation site of the enzyme, and an A->G in the first poly A addition signal6 (AATAAC->AGTAAC). The on the genomic DNA sequence in GenBank X52150 unless otherwise specified. Nucleotide 1 is the first coding nucleotide of the sequence which is position 630 in X52150. This follows the pattern of mutation position numbering used in a recent review.3
SITE DIRECTED MUTAGENESIS
An expression vector, pSVL-arylA, was created by inserting a full length arylsulphatase A cDNA into the pSVL vector. The A2 1 2V mutation was generated directly in the expression plasmids using a kit based on the "unique site elimination" method. 14 Plasmids were purified with QIAGEN (Studio City, California) columns and the sequence confirmed before use.
TRANSFECTIONS
Transient expression studies were performed using the normal and mutant pSVL-arylA expression vectors. AatII digestion ofPCR product with A212V mutation. The A212V mutation creates a new AatII site such that the 510 bp PCR product is cut to 335 bp and 175 bp fragments. Samples are shown -l+ AatII. Sample 1, control; sample 2, A212Vhomozygote, the probandfrom family 1 (VII.3 infig 1); sample 3, A212Vheterozygote, the father of the proband (VI. 14 in fig 1) . DNA standards (pBR3221Hinfl) are shown on the left.
The AatII digestion was also used for PCR products from patients 2 and 3 and showed that each of them was heterozygous for the A2 1 2V mutation (data not shown). Where DNA was available, family members were also tested, The results for family 1 are noted in the pedigree in fig 1. In family 2, the A2 1 2V mutation was inherited through the mother who was of French or Acadian descent and was inherited by two of six sibs (data not shown). Subsequent sequence analysis of segment D in patient 3 identified a second mutation in exon 3. This mutation, a T-*G at position 799, would cause an I179S amino acid alteration. This mutation has previously been described'8 in an adult onset patient of Swiss origin. In summary, the infantile onset MLD was associated with A2 1 2V/A2 1 2V, the juvenile with A2 1 2V/P426L, and the adult onset with A212V/I179S. The locations of these muta- The A212V mutation has been previously reported in one instance in a patient of British origin. 7 In that case, the mutation was heterozygous with an A224V in an adult onset MLD patient. Expression studies for these mutations were not reported so the severity of the mutation could not be accurately determined.
We have found the A212V mutation now in three patients, one of whom, an infantile onset case, is homozygous. We have also completed transient expression studies in heterologous COS cells. The alanine at position 212 is not conserved among the various sulphatases' and the A212V is a relatively minor alteration between two non-polar amino acids. However, the mutation virtually eliminates production of arylsulphatase A activity from the transfected plasmid. Although we do not know at what level the mutation exerts its effect, for instance, processing, substrate binding, etc, the effects of such a mutation on enzyme activity would be consistent with the extremely low enzyme activity found in fibroblast extracts from the homozygous, affected child and her severe early onset course. The results of the expression studies and the infantile onset of the disease in the homozygous affected child clearly indicate that this mutation causes a severe phenotype. The second mutations (P426L and I179S) found in the juvenile and adult onset patients respectively are known to be associated with somewhat milder forms of disease418 and are consistent with the phenotypes in these patients.
DNA testing of family members for the A212V mutation as well as other common mutations indicated that the Pd allele was also segregating in this family. In several cases, the presence of the Pd allele had resulted in people mistakenly designated as MLD carriers when assessment was based on arylsulphatase A activity alone. For such family members, genotyping has altered their apparent risk of producing a child with MLD.
The "A" allele mutation, P426L, has been calculated to occur in approximately 30% of MLD genes. The I179S mutation has a calculated frequency of 2%.' Until now recurrence of the A212V has not been reported. We have found the A212V mutation in three families with homozygosity in only one. In that case the kindred is highly consanguineous and a single allele from a common ancestor is the most likely explanation. In family 1, the subjects confirmed to have the A212V mutation are direct descendants of I.1, I.5, and I.6 (fig 1) , all of whom are cousins within family 1-P. Although we have not established a genealogical connection between families 1 and 2, the mother in family 2, the carrier of the A212V, also has French or Acadian heritage. Family 3 has a mixed western European background. Recurrence of the A212V allele is therefore unlikely to be the result of a recent founder effect, as has been observed for other disorders in specific Nova Scotian demes, including the prevalence of Fabry disease in Acadian Nova Scotians' and the clustering of neonatal hyperparathyroidism in south western Nova Scotians of British origin.20 For pseudo-vitamin D deficient rickets, linkage disequilibrium mapping of flanking polymorphic markers provides a genetic confirmation of the hypothesis that the prevalence of this recessive disorder in Acadians of Nova Scotia and the other Maritime Canadian provinces is the result of a founder effect that dates back to the earliest generations of Acadian settlement.2'
The original A2 1 2V mutation in the arylsulphatase A gene was reported in a person of British background,7 while British, Dutch, and French or Acadian origins are claimed by the three families reported here. Family 1-P had been settled in the Nova Scotia area before the British takeover in 1763. We suggest that the A2 1 2V mutation is likely to predate the founding settlements of Maritime Canada (1604-1800), but identification and mapping of flanking markers should allow for linkage disequilibrium analysis that could strengthen this hypothesis and yield a preliminary estimate of the date of origin.
